ArticleOpen forum infectious diseases2026
Clinical Characteristics and Outcomes of Bloodstream Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales in Argentina: A Subanalysis of the EMBARCAR Prospective Multicenter Cohort Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bloodstream infections (BSI) caused by metallo-beta-lactamase (MBL)-producing Enterobacterales (E) are associated with high mortality. However, in most Latin American countries there is a lack of clinical and microbiological data on BSI caused by MBL-E. Methods: This preplanned subgroup analysis of the multicenter, observational, prospective EMBARCAR study focused on adult patients with BSI caused by MBL-E in Argentina. Logistic regression adjusted by propensity scores (PS) for the treatment with ceftazidime-avibactam plus aztreonam (CAZ/AVI plus ATM) were used to identify variables associated with mortality. Results: A total of 140 patients with BSI caused by MBL-producing Enterobacterales were included. Median age was 59 years (IQR 46-70), and most patients were male (61%). Most frequent comorbidities were diabetes 23%, class III obesity 19%, and chronic renal failure 19%. Two thirds of patients were hospitalized in critical care units, 60% required mechanical ventilation and 38% presented with shock. Most frequent isolated microorganisms were Conclusions: In summary, BSI due to MBL-producing Enterobacterales resulted in a high mortality rate in our country. The use of CAZ/AVI plus ATM was associated with a decreased mortality. Better access to these antibiotics should be granted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.